INTRODUCTION
Despite its common practice, percutaneous biopsy within the context of a potentially malignant lesion remains controversial. 1 Clinical decision making is frequently enhanced when the pretreatment histologic diagnosis is ascertained. In the case of sarcoma, fine-needle aspiration biopsy may be sufficient to establish that the lesion in question is a malignant mesenchymal neoplasm; however, a core needle biopsy is required for the pretreatment assessment of histologic subtype and grade, features that guide the choice and sequencing of modern multimodality therapy. 2 For a core needle biopsy, the needle is typically 12-gauge to 16-gauge and 4 to 10 passes are obtained. [3] [4] [5] Obviously, the needle tract will breach the tumor pseudocapsule, and thereby could theoretically increase the risk of tumor dissemination. Despite the lack of good evidence of a substantive risk, the potential for biopsy-related cancer recurrence continues to be regarded as a significant concern by many physicians. 3 For each individual clinical presentation, thoughtful consideration should be given to the risk/benefit ratio of needle biopsy.
To the best of our knowledge, the literature regarding needle tract seeding (NTS) consists largely of case reports. Although these demonstrate that percutaneous biopsy can be followed by growth of tumor within the needle tract, they do not provide information regarding incidence or risks factors. In a survey of the literature, case reports of NTS were identified for many types of solid tumors including: sarcoma 6 , gastrointestinal (pancreas, 7-10 hepatocellular, 11 bile duct, 12 colorectal liver metastasis, 13 gastric, 14 and neuroendocrine 15 tumors), urologic (renal cell carcinoma, [16] [17] [18] [19] [20] [21] transitional cell carcinoma, 22 prostate cancer, 23 Wilms tumor, 24 and renal oncocytoma 25 ), respiratory (lung cancer 26 ), breast, 27,28 thyroid tumors 29 and melanoma. 30 Based on these limited data, it appears that the risk of NTS may be specific to the tumor histology. An example of a malignancy with a relatively high potential for NTS is hepatocellular carcinoma. A systematic review and meta-analysis published in 2008 by Silva et al estimated that the risk of NTS after biopsy for hepatocellular carcinoma was 2.7%. 31 Systematic reviews examining the incidence of NTS among other common malignancies that often undergo pretreatment needle biopsy, such as thyroid and prostate cancer, have yielded a much lower estimated risk (1%). 29, 32 For patients with sarcoma, the incidence of NTS is particularly obscure. Currently, hepatobiliary surgeons advocate for the use of imaging, serum tumor markers, and clinical acumen to guide the management of patients with undiagnosed liver lesions, rarely using pretreatment biopsy of resectable lesions due to the potential for inferior oncologic outcomes. 33 By contrast, in the case of sarcoma, clinical diagnosis without biopsy is frequently unreliable and insufficiently detailed, and therefore pretreatment biopsy is currently the standard of care. 34 It should be noted that the risk of NTS is not limited to biopsies. Other types of needle tracts, such as those generated during radiofrequency ablation or ethanol injection, [35] [36] [37] have also been associated with NTS. This review explores the seeding potential of sarcoma and attempts to ascertain the incidence of NTS in patients with extremity, intraperitoneal, and retroperitoneal sarcoma. The objective was to aid clinicians in weighing the risks and benefits of the pretreatment biopsy of suspected sarcoma.
Biologic Basis of Cellular Implantation
In 1889, Paget coined the expression "seed and soil" to describe patterns of metastasis in breast cancer. 38 This theory holds that a tumor embolus ("seed") is most likely to grow in surrounding tissue predisposed to supporting tumor growth ("soil"). More than a century later, the role of the microenvironment in facilitating the growth of metastatic cells remains the subject of active study. Stromal cells, which include cancer-associated fibroblasts and macrophages, have been identified as key regulators of tumor initiation, invasion, and metastasis. 39 It has been demonstrated that when tumors metastasize spontaneously, malignant cells are accompanied by stromal cells that facilitate initial implantation and growth in the secondary site. 40 Our laboratory currently is investigating the hypothesis that malignant cells and their stroma can adhere to the surgical instruments used during interventions that disrupt the tumor pseudocapsule, and that these cells can then be exfoliated in sites of subsequent physical contact. This is presumably the underlying mechanism of NTS. Although the reported incidence of NTS in patients with sarcoma is low, there are several reports of iatrogenic tumor seeding of sarcoma that may be analogous to NTS, demonstrating the implantation potential of malignant mesenchymal cells.
Hughes and Thomas reported the case of a patient who underwent resection of a recurrent spindle cell sarcoma en bloc with popliteal vessels. Vascular reconstruction used the contralateral long saphenous vein. Sixteen months later, a metastatic deposit was identified within the surgical scar at the site of the vein harvest. 41 Although hematogenous spread to a favorable wound microenvironment is a potential underlying mechanism for this pattern of spread, it was hypothesized that this represented iatrogenic seeding at the time of surgery. The authors attributed the seeding to surgical gloves or instruments that harbored shed malignant cells and surrounding stromal cells from the tumor resection site, which then were transferred to the vein harvest site. 41 Walsh and Nesbitt reported a case of metastasis at the port site in the chest wall 3 months after the patient underwent video-assisted thoracoscopic surgical resection of metastatic, high-grade lower limb sarcoma to the lung, 42 and Sartorelli et al reported on a patient with osteogenic sarcoma with lung metastases who developed a metastasis at the port site only a few months after undergoing video-assisted thoracoscopic surgical resection. 43 In neither of these cases was an endoscopic retrieval bag used. In the former case, disease recurrence occurred at all 3 port sites, suggesting a mechanism other than direct contact of the specimen with the port site wound; in the latter case, only the extraction port was involved. Although not examples of NTS, these cases demonstrate the ability of sarcoma to seed surgical wounds.
The development of sarcomatosis after the inadvertent intraperitoneal morcellation of uterine leiomyosarcoma is another manifestation of sarcoma's implantation potential. A retrospective, multi-institutional cohort study from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Massachusetts General Hospital demonstrated a >3 times increased risk of disease recurrence after morcellation (19 patients) compared with total abdominal hysterectomy for what proved to be a uterine leiomyosarcoma (39 patients). Patients in the morcellation group had higher rates of abdominal and pelvic disease recurrence and a significantly shorter recurrence-free survival (median, 10.8 months vs 39.6 months). 44 Heightened awareness of this phenomenon has led to a recent reexamination of common practice, and recommendations regarding the role of power morcellators in minimally invasive gynecologic surgery. 45, 46 Biopsy Needle Tract Seeding in Sarcoma/Berger-Richardson and Swallow
Cancer February 15, 2017 Harvest site wound recurrence, port site metastasis, and peritoneal sarcomatosis all are examples of malignant cell implantation that can occur in sarcoma, just as in carcinoma; disruption of the tumor surface can release tumor and stromal cells and lead to the seeding of favorable host sites. NTS can be regarded as another example of this phenomenon, and is indeed a potential risk when pretreatment biopsy is performed for probable mesenchymal tumors.
Incidence of NTS After Percutaneous Biopsy of Extremity Sarcoma
Although NTS after percutaneous biopsy of extremity sarcoma is a commonly cited risk, to the best of our knowledge there are very few data on which to base an estimate of its true incidence. In addition, the heterogeneity in methods of detection of NTS among published studies has created further interpretive challenges. In particular, studies that follow patients for NTS in unresected needle tracts cannot be compared directly with studies that document the routine excision and histologic examination of biopsy needle tracts. In the latter scenario, the identification of tumor cells cannot be equated with the eventual development of clinically apparent tumor nodules.
A systematic review published in 2014 queried the literature up to 2010 and identified 4 studies reporting on percutaneous biopsy tract recurrence in the setting of musculoskeletal sarcoma. 47 Oliveira et al published an additional cohort study on this topic. 48 We pooled the results of 3 of the above studies, [48] [49] [50] which described a total of 63 patients who underwent routine excision of the needle tract en bloc with primary surgical resection: 8 patients (13%) were found to harbor microscopic deposits of sarcoma cells within the needle tract (Table  1) . [48] [49] [50] [51] [52] However, among 30 patients who underwent surgical resection of the primary tumor without resection of the biopsy tract, there were no cases of disease recurrence noted within the in situ needle tract or other local recurrence after >4 years follow-up (pooled results of 2 studies). 51, 52 Although the number of cases was too limited to draw any definitive conclusions, this discrepancy suggests that even if malignant cells are deposited within the biopsy tract, this may not lead to a clinically significant disease recurrence. In the era of widely used neoadjuvant and adjuvant therapy, these retained cells may be of insufficient number to establish growth and attract a blood supply, etc. Conversely, all 5 cases of NTS identified in case reports that were compiled in the systematic review by Oliveira et al were cases in which the tract was left in situ. 47, [53] [54] [55] These isolated cases demonstrate the potential for NTS when the tract is not excised.
Despite the inability to define the incidence of NTS after percutaneous biopsy of extremity sarcoma, certain measures have been recommended to potentially decrease the risk of its occurrence. The usefulness of needle tract resection during definitive tumor resection has been inferred from case reports such as those mentioned above, but to the best of our knowledge has not been proven. Given that NTS is a very uncommon outcome, the value of resecting the needle tract has been evaluated by assessing the rate of local disease recurrence, a surrogate outcome, when the needle tract is either left in situ or resected. Binitie et al 56 reported a retrospective case series of 59 patients who had undergone resection of a highgrade, deep extremity sarcoma measuring >5 cm, without resection of the core needle biopsy tract, with a median follow-up of 56 months. The local recurrence rate was 9%, similar to rates reported in such patients when the tract is excised. 57, 58 In the series by Binitie et al, 56 97% of the patients received preoperative or postoperative radiation and 83% received chemotherapy. The authors concluded that leaving the biopsy tract in situ did not appear to increase the risk of local disease recurrence. 56 Other authors and experts have proposed precautions with respect to the pathway of the biopsy tract. Guidelines have recommended that the needle not traverse uninvolved muscle compartments, joint spaces, or neurovascular bundles. 59 UyBico et al retrospectively reviewed 363 consecutive patients who underwent computed tomography-guided percutaneous biopsy of extremity lesions to determine whether breaches in biopsy technique were associated with NTS. 60 A total of 188 lesions were malignant, 67% of which were soft tissue sarcoma whereas 33% arose from bone. Biopsy breaches were defined as one or more of: the needle crossing >1 anatomic compartment, the needle traversing prespecified vital structures (eg, joint capsules, arteries, or nerves), or the needle not following predetermined biopsy paths for bone lesions set by the published guidelines. 61, 62 Approximately 4% of biopsies (13 biopsies) crossed anatomic compartments, 12% (42 biopsies) traversed "vital structures," and 68% of biopsies of bony lesions (82 biopsies) did not follow the recommended path. Despite these breaches, at follow-up times of 24 to 96 months, no NTS had been identified in any of the patients. 60 For patients with suspected sarcoma, the rationale for the proper planning of the needle pathway into the tumor, and for routine excision of the needle biopsy tract should the diagnosis prove to be sarcoma, would appear sound based on intuition and oncologic principles, but not grounded in clinical evidence, other than a few published case reports.
Percutaneous Biopsy of Intraperitoneal Sarcoma
Gastrointestinal stromal tumors (GISTs) are often biopsied before treatment. In the neoadjuvant setting, definitive diagnosis is preferred before the instigation of preoperative imatinib therapy. 63 In addition, an alternative diagnosis, such as lymphoma, should be ruled out before surgical resection, because the latter may be treated with chemotherapy alone 64 whereas other entities such as ectopic pancreas may require no treatment. The trajectory of a transperitoneal biopsy usually does not create a defined tract as noted in extremity biopsies, and theoretically puts patients at risk of peritoneal dissemination. 3 However, despite this oft-quoted theoretical risk, to our knowledge no case of tumor dissemination in GIST has been unequivocally attributed to percutaneous biopsy. Guidelines published by the National Comprehensive Cancer Network state "GISTs may be soft and fragile, and biopsy may cause hemorrhage and increase the risk for tumor dissemination." 65 Endoscopic ultrasound (EUS)-guided biopsies have been suggested to decrease the potential risk of seeding by shortening the tract or avoiding transperitoneal needle passage altogether, and currently are more commonly used for suspected GISTs of the stomach, duodenum, and rectum. 66 The improved oncologic safety of EUS-guided biopsy compared with percutaneous biopsy for presumed GIST has been suggested from reports in patients with other cancer types. A review article by Jenssen et al reported the overall risk of tumor cell seeding after EUS-guided biopsy to be in the range of 0.003% to 0.009% in all types of malignancy considered together. 66 In a retrospective review of patients with pancreatic cancer, rates of peritoneal carcinomatosis were found to be lower among patients who underwent EUS-guided biopsy compared with those who underwent percutaneous biopsy. 67 In none of 6 reported cases of tumor seeding after EUS was the primary tumor a GIST. 68 Eriksson et al recently reported cancer-related outcomes in patients enrolled in the Scandinavian Sarcoma Group XVIII/Arbeitsgemeinschaft Internistische Onkologie randomized trial of 1 year versus 3 years of adjuvant imatinib after surgical resection of high-risk GIST. Patients who had undergone pretreatment percutaneous biopsy (47 patients) were found to have equivalent recurrence-free and overall survival compared with patients who did not undergo percutaneous biopsy (346 patients). 69 Although to the best of our knowledge this is the largest study to suggest the safety of percutaneous biopsy in patients with GIST, the results may not be generalizable to patients who are not destined to receive perioperative imatinib.
In the setting of a resectable, curable primary uterine leiomyosarcoma, the diagnosis currently is seldom confirmed preoperatively. Percutaneous biopsy is not favored by the gynecologic community; if a pretreatment diagnosis is desired, sampling via the uterine cavity may be possible, although sampling error represents a significant challenge. To our knowledge, there is no significant published experience with percutaneous biopsy.
Percutaneous Biopsy of Retroperitoneal Sarcoma
Percutaneous biopsy of retroperitoneal sarcoma (RPS) can usually be accomplished via a needle tract that does not transgress the peritoneal cavity. However, definitive surgical resection is often performed via a transperitoneal approach, typically leaving the needle tract in situ. However, concern for disease recurrence in the needle tract is dampened by experiences at several sarcoma specialist units, including those at the Royal Marsden Hospital 70 ; the Sydney Sarcoma Unit 71 ; the National Cancer Institute in Milan, Italy; and the Mount Sinai Hospital/Princess Margaret Cancer Centre in Toronto, Ontario, Canada. Pooled data from these 4 institutions demonstrated that there were 2 cases of presumed NTS out of 547 patients who underwent percutaneous core needle biopsy of what proved to be primary RPS (0.37%) ( Table 2) . 70, 71 We performed a retrospective review of consecutive patients who underwent percutaneous core needle biopsy before surgical resection of nonmetastatic primary RPS at Mount Sinai Hospital in Toronto, Ontario, Canada, from 1996 through 2013. Of 166 patients, 142 (86%) received preoperative radiotherapy (10 with postoperative brachytherapy), whereas 24 patients (14%) did not receive any form of radiotherapy. Of these 166 patients, 13 (8%) received perioperative chemotherapy. At a median followup of 44 months, 35 patients had developed local disease recurrence (21%) and 19 patients (11%) had developed distant disease recurrence. Only 1 patient in this cohort developed a recurrence that was potentially consistent with NTS: the patient had what at the time was called high-grade malignant fibrous histiocytoma, and presented with a large retroperitoneal mass invading the anterior abdominal wall, the posterior abdominal wall, and the paraspinal muscles, intercalated between ribs 10 through 12 posteriorly. The mass initially had been deemed unresectable, and grew despite external beam radiotherapy. The patient then was treated with doxorubicin, with an eventual decrease in the size of the mass and development of necrosis. An extensive surgical resection subsequently was undertaken and the patient recovered well postoperatively. However, 9 months after the surgical resection, there was evidence on computed tomography of 3 nodules within a cluster, each measuring 1 to 2 cm, on the posterior fascial surface of the paraspinal muscles. Core needle biopsy confirmed recurrent disease, with the histologic appearance matching that of the primary tumor. The recurrent tumor was excised using a posterior approach. The location of the recurrence was consistent with NTS.
On review of the literature, we identified 1 additional case report of a patient who, 5 years after undergoing surgical resection of a primary retroperitoneal liposarcoma, developed a nodule within the needle biopsy tract with the same histologic appearance as the primary tumor. 6 Taken together with the multi-institutional RPS experience described above, we conclude that RPS can be safely biopsied percutaneously, with a very low risk of NTS.
Conclusions
To the best of our knowledge, there is a paucity of goodquality evidence regarding the incidence of clinically relevant NTS after percutaneous biopsy of sarcoma of the extremity, peritoneal cavity, and retroperitoneum. In the absence of a prospective study in which patients with sarcoma have been specifically followed for NTS with highly focused and sensitive imaging techniques at prescribed intervals, we are limited in estimating the incidence of NTS. For each of the 3 sites, the incidence appeared to be <1%, and most likely is significantly less in the modern era, given the widespread use of coaxial sheathed biopsy needles (Fig. 1) . The long-term clinical outcomes that have been documented in prospective and retrospective studies suggest that patients who have undergone percutaneous needle biopsy do not have any increased risk of developing local recurrence of sarcoma.
Nonetheless, we would recommend that the needle trajectory should be considered when planning a percutaneous biopsy, and that the approach should be discussed with the treating clinician, in particular the surgeon. This type of discussion is facilitated within the context of a multidisciplinary team at an experienced sarcoma center. A review of the cross-sectional imaging at a multidisciplinary tumor board will facilitate the targeting of highyield areas of the tumor, and promote an understanding of the amount of lesional material desired for routine histologic, immunohistochemical, and molecular pathologic examinations.
Taking a step back, it should be emphasized that it is important to first consider whether a percutaneous biopsy is indeed going to add information and influence decision making for the individual patient. A detailed review of the imaging by a radiologist who has experience and expertise in interpreting soft tissue and bone lesions together with an experienced clinician who has evaluated the patient is required before making a decision to perform biopsy. A pretreatment biopsy not only rules out other pathologies that should be treated differently, if at all, it also establishes the detailed diagnosis that permits optimal multimodality treatment of sarcoma and surgical planning. On balance, when sarcoma is suspected, a pretreatment biopsy can be performed safely without compromising oncologic outcomes, and is recommended to formulate the most effective treatment strategy for the individual patient.
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